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Introduction
Diabetes mellitus (DM) is a group of metabolic 
diseases characterized by an increase in blood 
glucose levels, or hyperglycemia, resulting from 
inadequate secretion or action of insulin 
preventing glucose from being absorbed into the 
cells (McCance and Huether, 2014). 
• Nearly 9.3% of the U.S. population and 26% 
of Americans age 65 and older had diabetes
• Diabetes is the 7th leading cause of death in 
the U.S (Centers for Disease Control and 
Prevention, 2014). 
• One of the major complications of DM 
includes diabetic nephropathy, also known 
as diabetic kidney disease
Diabetic Nephropathy is defined as 
progressive disease or damage to the kidneys 
caused by the metabolic and hemodynamic 
changes in diabetes. This condition is 
characterized by persistent albuminuria, a decline 
in the glomerular filtration rate (GFR), and 
elevated arterial blood pressure (Jaipaul, 2013).
• Leading cause of end-stage renal disease, 
and associated with increased 
cardiovascular mortality (Jaipaul, 2013). 
• Approximately 30% of individuals with type 
1 diabetes mellitus and 40% of individuals 
with type 2 diabetes mellitus will develop 
diabetic nephropathy (McCance and 
Huether, 2014). 
As a healthcare professional, having an 
understanding of the complex pathophysiology of 
diabetic nephropathy and the most appropriate 
screening, prevention, and treatment options 
available is vital for the management of the 
diabetic patient population. Development of this 
progressive kidney disease would have life-long 
effects on quality of life as meticulous monitoring 
and treatment is required to slow the progression 
of the disease. 
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Pathophysiology
Conclusion
The main pathophysiology changes in diabetic nephropathy comprises of a complex network of events 
leading to damage of the glomerular filtration membrane (GFM), irreversible damage to glomerular capillaries 
and loss of kidney function (Sego, 2007). The GFM is comprised of three layers: the glomerular endothelium, 
the glomerular basement membrane, and the epithelial podocytes, that permits a highly selective 
ultrafiltration of the blood plasma and maintains a balance of vasoconstriction and dilation. Other key changes 
include: mesangial cell expansion, Kimmelstiel–Wilson nodules, glomerulosclerosis, and tubular interstitial 
fibrosis (Zheng and Zheng, 2015). These changes occur due to both genetic and environmental factors 
associated with diabetes, the most significant being hyperglycemia and hypertension. An early physiologic 
abnormality is glomerular hyperfiltration and intra-glomerular hypertension, accompanied by the onset of 
microalbuminuria (Mora-Fernández, 2014). The cellular elements of the kidney respond to hyperglycemia by 
various pathways: hemodynamic, metabolic, and inflammatory (Toth-Manikowski and Atta, 2015).
Hemodynamic Pathway:
The hemodynamic dysfunction includes intra-glomerular hypertension and hyperfiltration as a result of 
efferent arteriole vasoconstriction due to activation of the renin-angiotensin-aldosterone-system (RAAS) (Toth-
Manikowski and Atta, 2015). Hyperglycemia stimulates the RAAS resulting in increased intra-glomerular 
capillary pressure. Angiotensin II actives pathways which induce inflammation, renal cell growth (mesangial 
expansion) and apoptosis of podocytes (Mora-Fernández, 2014). Hyperglycemia also impairs the 
autoregulatory mechanism that maintains normal glomerular perfusion and glomerular filtration rate (GFR), 
initially resulting in an increase in GFR. This elevated intra-glomerular pressure stimulates several responses 
within the glomerular capillary bed: thickening of endothelial mesangial cells and the glomerular basement 
membrane, and loss of selective permeability. Microalbuminuria develops as well as impairment of nitric oxide 
(NO) transport (Sego, 2007).
Metabolic Pathway:
In metabolic dysfunction, hyperglycemia leads to increased glycolysis, the process by which cells break 
down glucose to make energy, which upregulates four pathways. The polyol pathway results in the conversion 
of glucose to sorbitol, causing decreases in nitric oxide and contributing to intracellular stress and apoptosis. 
Sorbitol is then converted into fructose which has been identified as a nephrotoxin leading to increased 
proteinuria, decreased GFR, and increased superoxide levels and inflammatory cytokines (Toth-Manikowski
and Atta, 2015). The second hexosamine pathway stems from a step in glycolysis in which fructose-6-
phosphate is converted to glucosamine-6-phosphate and used to increase inflammatory cytokines: tumor 
necrosis factor-a and transforming growth factor-B1 which promotes renal cell hypertrophy (Toth-Manikowski
and Atta, 2015). The third pathway includes the formation of advanced glycation end-products (AGEs), which is 
a bond between glucose and proteins. AGEs directly accelerate the vascular complications of diabetes. 
Intracellular AGEs lead to expression of cytokines and growth factors that contribute to glomerular sclerosis 
and tubulointersitial fibrosis. Extracellular AGE accumulation can cause structural changes including a 
thickening of the glomerular basement membrane (GBM) due to leukocyte and platelet adhesions and 
accelerate endothelial dysfunction resulting in leakage of serum proteins (Mora-Fernández, 2014). AGEs also 
have the ability to bind to pro-inflammatory receptors; modulating cell functions, activating the production of 
cytokines, and increases generation of reactive oxygen species (ROS) (Toth-Manikowski and Atta, 2015). The 
final pathway stems from the final step in glycolysis in which glyceraldehyde-3-phosphate is converted into a 
cofactor that activates protein kinase C (PKC). PKC increases activity of prostaglandin E2 and nitric oxide (NO) 
causing vasodilation of the afferent arteriole leading to glomerular hyperfiltration (Toth-Manikowski and Atta, 
2015). PKC also contributes to GBM thickening and extracellular matrix (ECM) accumulation which alters the 
capillary permeability allowing larger protein molecules (albumin) to enter the vasculature (Mora-Fernández, 
2014). 
Inflammatory Pathway:
The inflammatory pathway is caused by the chronic inflammatory state of diabetics (Hojs, Ekart, Bevc, Hojs, 
2015). Damage to renal cells release signals that triggers remodeling processes activating immune cells of the 
innate and adaptive response systems. Inflammatory cytokines increase vascular endothelial cell permeability, 
influence GMB thickening, and fibrosis develops and progresses (García-García et al, 2014).
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• Provide diabetes education and support, including 
education related to complications such as 
diabetic nephropathy
• Patients must have an understanding of 
medications, diet, laboratory values, and basic 
knowledge of anatomy and physiology associated 
with their disease to facilitate better 
understanding and compliance
• Diabetic nephropathy is very common, 
asymptomatic until late, and should be considered 
in all patients with diabetes: screening should 
begin immediately after diagnosis in patients with 
type 2 diabetes and within 5 years of diagnosis for 
type 1 diabetics (Lewis and Maxwell, 2014)
• Measure albumin in a spot urine sample, collected 
either as the first urine in the morning or at 
random (Gross et al., 2015)
• Monitor renal function: GFR and serum creatinine 
(Gross et al., 2015)
• Obtain renal ultra sound looking for hypertrophy 
(Butt, Hall, and Nurko, 2010)
• When prevention fails and the diabetic state does 
exist, rigid control of hyperglycemia (maintain 
HbA1cat ≤ 7.0) with a combination of with diet, 
exercise, and medications
• Treat BP aggressively, usually beginning with 
angiotensin inhibition (Sego, 2007)
• Other considerations include: lipid management, 
protein restriction, vitamin D supplementation 
(Quiroga, Arroyo, & de Arriba, 2015)
• In patients with kidney failure, emotional support 
and education regarding renal replacement 
therapy is important, as well as continued strict 
glycemic control to prevent further complications 
including: diabetic retinopathy, peripheral 
vascular disease, cardiovascular disease, etc
(Sego, 2007).
The most common cause of ESRD in the United 
States today is diabetic nephropathy, and the incidence 
of type 2 diabetes is increasing. Several factors 
contribute to renal damage, including hyperglycemia, 
hypertension, and a genetic predisposition in some 
patients. The best treatment for diabetic nephropathy is 
prevention. Once nephropathy is present, progression 
cannot be avoided, only delayed. The earliest clinical 
indicator of renal damage is microalbuminuria; 
therefore, any patient diagnosed with diabetes should 
be screened for diabetic nephropathy at regular 
intervals with sensitive tests (Evans and Capell, 2015). 
Patient education, strict glucose and blood pressure 
control including medications and lifestyle changes, and 
regular testing is essential for adequate treatment of 
the diabetic patient to prevent this incurable 
complication. 
Signs and Symptoms
• Asymptomatic in early stages
• Sustained microalbuminuria followed by 
macroalbuminuria
• Hypertension
• Dependent Edema
• Nausea, vomiting, weakness
• Increased BUN and/or creatinine
Significance of Pathophysiology
Understanding the pathophysiology of chronic diabetic 
nephropathy will allow health care providers to identify risk factors 
and provide appropriate preventative treatments such as 
medication regimens, laboratory testing and screenings; as well as 
aid in early detection, diagnosis, and maintenance to slow further 
progression of the disease. 
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